AI summary by TwinMind

Weight Loss Drugs Before Ozempic

Asianometry

29m 11s

Current Obesity Crisis

  • 2022 CDC data: 42% of Americans classified as obese (BMI >30)
  • Obesity responsible for up to 14 years lost life expectancy
    • Primarily through cardiovascular disease
  • US spends nearly $200 billion annually treating obesity-related diseases
  • Costs projected to rise in near future

Weight Loss Treatment Approaches

  • Lifestyle/behavior changes: easiest but often ineffective for lasting weight loss
  • Bariatric surgery: most effective but carries surgical complications
  • Pharmacology: intermediate option with troubled history

Three Drug Mechanisms

  • Appetite suppression: modifying neurotransmitter release/reabsorption in brain
  • Increased energy expenditure: raising metabolism (e.g., caffeine, ephedrine)
  • Digestive interference: blocking fat absorption from food

Ancient and Early Treatments

  • Second century Greek doctor Siranis of Ephesus: prescribed exercise, heat, massage, laxatives, purgatives
  • Roman doctors: recommended vomiting with vinegar, salt water, half cup hyssop plant
  • 956 AD: Sancho the Fat (King of Leon) treated with teresia fairacia
    • 64 ingredients including opium, ginger, cinnamon, saffron, castor oil
    • Successfully lost weight, retook throne

Early Scientific Era (1880s-1930s)

  • Late 19th century: industrialization created demand for weight loss drugs
  • Thyroid extract treatment:
    • Doctors noticed hypothyroidism caused weight gain
    • Sheep-derived thyroid extracts reversed symptoms including weight
    • Early 1890s: clinical reports on thyroid hormone for obesity
    • Drawbacks: abnormal heart rhythm, dangerously high heart rate, possible heart failure

Quack Medicine Era

  • Turn of century: proliferation of fake medicines claiming miracle cures
  • Names: Allen's Anti-Fat, Frank J Kellogg's Fat Reducer, Marmola, Newman's Obesity Cure, Dr Gordon's Elegant Pill
  • Common ingredients: thyroid extract, vomiting agents, appetite suppressants, stimulants
  • 1906 Pure Food and Drug Act: limited FDA authority
  • 1911 US v. Johnson: Supreme Court ruled act only covered ingredient claims, not therapeutic effects
  • 1912 Sherley Amendment: banned misbranding but required proving fraud, not just falsehood
  • Created 50-year loophole hampering FDA enforcement

DNP Era (1933-1937)

  • Dr Maurice Tainter at Stanford reported 2-4 dinitrophenol (DNP) weight loss properties
  • DNP also used for explosives, dye, wood preservative, herbicide
  • Discovery: French WWI soldiers/factory workers grew thin after DNP exposure
  • Dosage: 3-5 mg/kg initial weight daily = 1.5 kg weight loss per week
  • Mechanism: disrupts mitochondrial ATP production, wastes energy as heat
  • Risks: hyperthermia, tachycardia, fatal intoxication, cataracts
  • Usage: Stanford applied 1.2 million capsules to patients, 100,000+ people took them
  • 1935: FDA issued concern but lacked regulatory authority
  • 1937 Elixir Sulfanilamide crisis: 100 children died from antifreeze additive
  • 1938 Federal Food Drug and Cosmetic Act: gave FDA authority
  • FDA removed DNP after 2,500 cataract reports
  • Resurfaced in 1980s Texas, still sold online for bodybuilders

Amphetamine Era (1930s-1960s)

  • Mechanism: rapid dopamine release, energy rush, increased metabolic rate
  • 1933: Smith Klein & French sold Benzedrine as decongestant
  • 1935: UC San Francisco study for narcolepsy noted weight loss
  • 1947: FDA approved methamphetamine (dysoxy ephedrine) for obesity
    • 3 daily doses of 2mg could lose up to 25kg
    • Major problem: highly addictive

Rainbow Pills (1941-1968)

  • Clark and Clark produced diet pills: amphetamine sulfate + thyroid hormone
  • Called "Clark attacks" but branded as "rainbow pills" due to colors
  • Sold directly to physicians, bypassing pharmacies
  • 1967: 5,000 doctors, 2,000 practices earning $250M fees + $125M pills
  • Legal but acknowledged as low ethics
  • FDA struggled with action due to:
    • Loopholes in 1938 act
    • Ingredients already approved for other uses
    • Little evidence of harm
    • Hesitancy to interfere with medical practice
    • Industry money and aggressive marketing
  • 1968 Life magazine investigation: reporter got 1,500 pills from 10 clinics
  • Senate subcommittee: identified 60+ deaths from rainbow pills
  • January 1968: FDA seized 43 million tablets from dozen manufacturers
  • 1970s: FDA reconsidered amphetamines for weight loss entirely

Amphetamine Congeners (1950s-1970s)

  • Goal: create similar effects without addictiveness
  • Phenometrazine (Preludin): approved 1956, eventually found addictive, caused delusions/paranoia
  • Phentermine: approved 1959, became exception that survived
    • 2019: 3 million prescriptions, 75% US anti-obesity market share
    • Cheap generic, works first 12 weeks only
    • Long-term complications: palpitations, tachycardia

Fen-Phen Era (1970s-1997)

Background

  • Aminorex (1960s): developed by McNeil, sold in Germany/Austria/Switzerland
  • Caused 10x increase in primary pulmonary hypertension (PPH)
  • PPH: rare condition (1-2 per million), lung blood vessel narrowing, can be fatal
  • Swiss study: 71 hospitalized, 34 died
  • Drug pulled 1972, epidemic ended

Fenfluramine Development

  • 1973: fenfluramine hit market as amphetamine congener
  • Different mechanism: releases serotonin, increases fullness, suppresses appetite
  • Non-addictive, didn't affect motor activity
  • 1981: first PPH reports with fenfluramine
  • Problem: didn't work well alone, weight regain occurred

Fen-Phen Combination

  • 1979: Dr Michael Weintraub (University of Rochester) combined fenfluramine + phentermine
  • 28-week pilot study: combination worked "fantastically"
  • Fewer side effects than single drugs
  • NIH longer study: week 34 patients lost 15.9% initial weight (14kg/30lbs) vs 4.9% placebo
  • 1992: Clinical Pharmacology and Therapeutics published study
  • Fen-phen went viral, patients demanded prescriptions

Prescription Explosion

  • Phentermine: 1M prescriptions (1991) → 2.3M (1995) → 5M (1996)
  • Fenfluramine: 100K prescriptions (1994) → 800K (1995) → 3.8M (1996)
  • Entire practices devoted to dispensing fen-phen

Dexfenfluramine Approval

  • Companies wanted more specific variant: dexfenfluramine
  • September 1995 FDA vote: aware of PPH connection (10x risk increase)
  • Initial vote: 5-3 rejection
  • Second vote after impassioned plea: 6-5 approval
  • April 1996: FDA approval with cautionary warnings (ignored)
  • June 1996: hit shelves as "Redux" with massive advertising
  • 5 months: 1.2 million prescriptions

Heart Valve Discovery

  • December 1994: two echocardiography technicians in Fargo, ND noticed heart valve abnormalities
  • Tracked over 2 years: rare but always connected to fen-phen
  • February 1997: Mayo Clinic collaboration
  • Mechanism: fenfluramine stimulates serotonin receptors on heart valves
    • Stimulates protein growth on valve leaflets
    • Makes valves thick and leaky
    • Causes blood regurgitation, cardiac damage
  • June 1997: New England Journal of Medicine accepted article (24 cases)
  • July 1997: joint press release by journal, Mayo Clinic, FDA
  • September 1997: American Home Products pulled from market
  • 9,000 lawsuits filed, $3.75 billion settlement

Recent Failures (2000s-2010s)

Rimonabant (2006-2009)

  • Developed by Sanofi-Aventis to block cannabinoid receptors (opposite of marijuana munchies)
  • Rat studies: 21% weight loss
  • 2-year human trial: 8.6kg loss vs 2-3kg placebo (net 5-6kg)
  • Europe approved as "Acomplia"
  • US FDA rejected due to depressive disorders in 10% of patients
  • 1% had serious self-harm thoughts
  • Withdrawn from Europe 2009

Sibutramine (1980s-2010)

  • Originally developed by Boots Pharmaceutical UK for depression
  • 1988: noticed weight loss in trials
  • Mechanism: blocks reabsorption of norepinephrine, serotonin, dopamine
  • Results: 12% weight loss after 6 months
  • Side effects: higher blood pressure, heart rate
  • 1997: US FDA approved
  • 2003-2005: Scout study with 10,000+ obese individuals
  • Results: 11.4% cardiovascular complications vs 10% placebo
  • October 2010: pulled from market

Current State and Future

  • Growing obesity epidemic needs solutions
  • Century+ history of weight loss drugs full of setbacks
  • Pattern: incredible hype → withdrawal after problems discovered years later
  • Current drugs have modest effects: 4-6kg additional loss vs placebo over 6-12 months
  • Patients have unrealistic expectations, leading to discontinuation
  • New category: GLP-1 agonists (glucagon-like peptide 1) seem promising
  • History suggests caution despite apparent breakthroughs

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome